Combination of potential biomarkers may help predict response to immunotherapy in kidney cancer

Currently, it is difficult for clinicians to decide which patients will respond to immunotherapy and, therefore, what is the best course of treatment for patients with metastatic renal cell carcinoma (RCC). A recent study published in Oncoimmunology describes a combination of two potential biomarkers that may help predict response to immunotherapy for metastatic RCC patients, […]

read more

Potential biomarker for response to nivolumab for kidney cancer

Nivolumab was the first immunotherapy to be approved for the second-line treatment of metastatic renal cell carcinoma (RCC). Although some patients have long-lasting responses to nivolumab, others have limited benefit and the majority of patients will eventually experience disease progression. There has been a lot of research to identify a biomarker for response to nivolumab, […]

read more

Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab

In a paper published in Clinical Genitourinary Cancer the link between immune-related adverse events and clinical outcomes in patients with metastatic renal cell carcinoma (RCC) was investigated. One hundred and sixty seven (167) patients were included in the study. Of these, 46% had an immune-related adverse event, of which 8.9% were severe or life-threatening. However, […]

read more

ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer

Results from the phase II FRACTION-RCC clinical trial to assess the nivolumab plus ipilimumab combination in previously treated advanced renal cell carcinoma (RCC) patients were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. The study looked at 46 patients with previously treated RCC that was not responding to […]

read more

ASCO 2020: Optimised treatment of advanced kidney cancer with nivolumab and ipilimumab

Two studies were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to investigate whether initial treatment of metastatic renal cell carcinoma (RCC) patients with nivolumab followed by the addition of ipilimumab for patients with either stable or progressive disease would be as effective as upfront combination therapy and with less side […]

read more

Positive results from trial of cabozantinib plus nivolumab combination in untreated metastatic kidney cancer

Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating nivolumab (Opdivo) in combination with cabozantinib (Cabometyx) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (RCC) were released today. These top-line results were positive for the combination treatment, which improved progression-free survival, overall survival and objective response rate compared to sunitinib. […]

read more

Nivolumab for the treatment of metastatic non-clear cell renal cell carcinoma

Nivolumab alone and in combination with ipilimumab is used for the treatment of patients with metastatic renal cell carcinoma (RCC) in the second- and first-line, respectively. However, since patients with non-clear cell RCC are excluded from clinical trials, there is limited data on the effectiveness of nivolumab for the treatment of these patients. In a […]

read more

ASCO GU 2020: Immunotherapy combinations effective for brain metastases

Two small studies reported on patients whose kidney cancer had spread into the brain at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held in San Francisco last weekend. The first study was a real-world report of 17 patients with advanced kidney cancer in the brain. The patients were treated with ipilimumab and […]

read more

ASCO GU 2020: New drug, sitravatinib in combination with nivolumab for second-line treatment of advanced kidney cancer

The results from one of the first clinical trials of a combination of a new drug, sitravatinib, with nivolumab for the second-line treatment of advanced kidney cancer were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. Sitravatinib is a type of drug called a tyrosine kinase inhibitor […]

read more

ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab

Five-year follow-up results from the phase 3 CheckMate-025 study, which compared nivolumab (Opdivo) with everolimus in previously treated advanced or metastatic renal cell carcinoma (RCC), were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. Nivolumab continues to show superior overall survival and objective response rates […]

read more
Showing 1 to 10 of 113 results
  TOP